“Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing remitting multiple sclerosis.”
This is what NICE has decided in its final appraisal determination, available online today.
What does it mean ‘within its marketing authorisation’?
Here it is – the European Medicines Agency’s marketing authorisation: “LEMTRADA [alemtuzumab] is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS) with activedisease defined by clinical or imaging features.”
This is the final breakthrough for alemtuzumab in England and Wales (NI hopefully to follow soon, and Scottish Medicinces Consortium due to publish their verdict in May), and fantastic news for people with relapsing MS as it means alemtuzumab will now indeed be available on the NHS. A great achievement; many congratulations to all involved in the development of this drug, notably the MSers taking part in the trials! What a difference compared to the situation in the US!
It is now only a few months until the first people with relapsing MS will receive Lemtrada on the NHS, so here’s a taster of how convenient treatment with alemtuzumab can be (5 infusions in the first, and 3 in the second year)…
…and the commitment it involves to monitor for side effects: